First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis


Citar

Texto integral

Resumo

Myelofibrosis is one kind of bone marrow blood cancer that gives mainly bone marrow scarring. JAK families include JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) and they control hematopoiesis and immune cell function. JAK-STAT pathways have the critical roles in the pathogenesis of a variety of autoimmune and inflammatory diseases such as myelofibrosis. The 8 JAK inhibitors are approved by the US FDA for the treatment of various diseases. Abrocitinib, baricitinib, oclacitinib, ruxolitinib, tofacitinib, upadacitinib, fedratinib, and pactrinib with their IC50 values against JAK1, JAK2, JAK3, and TYK2 are included. All approved JAK inhibitors with structural similarities and dissimilarities are summarized. The development story of pacritinib and new design route to overcome intellectual property-related issues by connecting the A ring and C ring to form the macrocyclic compounds like 16 without compromising the binding modes in the hinge region are discussed. By using the powerful ring-closing metathesis (RCM), they designed and synthesized and delivered FDA approved pacritinib. In this short perspective, the chemical structure, physicochemical properties, mechanism of action, drug-interactions, adverse events, and pharmacokinetic profile of pacritinib are summarized. Detailed step by step synthesis of pacritinib is provided. Pacritinib is an orally bioavailable and isoform selective JAK-2 inhibitor for the treatment of patients with myelofibrosis. Detailed metabolism pathway with proper explanation is discussed.

Sobre autores

Surya De

Department of Chemistry, Conju-Probe

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Tefferi, A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 2014, 89(9), 915-925. doi: 10.1002/ajh.23703 PMID: 25124313
  2. Finazzi, G.; Vannucchi, A.M.; Barbui, T. Prefibrotic myelofibrosis: Treatment algorithm 2018. Blood Cancer J., 2018, 8(11), 104. doi: 10.1038/s41408-018-0142-z PMID: 30405096
  3. Chou, J.M.; Li, C.Y.; Tefferi, A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk. Res., 2003, 27(6), 499-504. doi: 10.1016/S0145-2126(02)00268-0 PMID: 12648509
  4. Stein, B.L. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options. Leuk. Lymphoma, 2022, 64(2), 1-8. doi: 10.1080/10428194.2022.2136970 PMID: 36301740
  5. Komrokji, R.S.; Seymour, J.F.; Roberts, A.W.; Wadleigh, M.; To, L.B.; Scherber, R.; Turba, E.; Dorr, A.; Zhu, J.; Wang, L.; Granston, T.; Campbell, M.S.; Mesa, R.A. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood, 2015, 125(17), 2649-2655. doi: 10.1182/blood-2013-02-484832 PMID: 25762180
  6. Mesa, R.A.; Vannucchi, A.M.; Mead, A.; Egyed, M.; Szoke, A.; Suvorov, A.; Jakucs, J.; Perkins, A.; Prasad, R.; Mayer, J.; Demeter, J.; Ganly, P.; Singer, J.W.; Zhou, H.; Dean, J.P.; te Boekhorst, P.A.; Nangalia, J.; Kiladjian, J.J.; Harrison, C.N. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol., 2017, 4(5), e225-e236. doi: 10.1016/S2352-3026(17)30027-3 PMID: 28336242
  7. Mascarenhas, J.; Hoffman, R.; Talpaz, M.; Gerds, A.T.; Stein, B.; Gupta, V.; Szoke, A.; Drummond, M.; Pristupa, A.; Granston, T.; Daly, R.; Al-Fayoumi, S.; Callahan, J.A.; Singer, J.W.; Gotlib, J.; Jamieson, C.; Harrison, C.; Mesa, R.; Verstovsek, S. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis. JAMA Oncol., 2018, 4(5), 652-659. doi: 10.1001/jamaoncol.2017.5818 PMID: 29522138
  8. Salit, R.B. The role of JAK inhibitors in hematopoietic cell transplantation. Bone Marrow Transplant., 2022, 57(6), 857-865. doi: 10.1038/s41409-022-01649-y PMID: 35388118
  9. Roskoski, R. Jr Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol. Res., 2022, 183, 106362. doi: 10.1016/j.phrs.2022.106362 PMID: 35878738
  10. William, A.D.; Lee, A.C.H.; Blanchard, S.; Poulsen, A.; Teo, E.L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E.T.; Goh, K.C.; Ong, W.C.; Goh, S.K.; Hart, S.; Jayaraman, R.; Pasha, M.K.; Ethirajulu, K.; Wood, J.M.; Dymock, B.W. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetra-cyclo19.3.1.1(2,6).1(8,12)heptacosa-1(25),2(26),3,5,8,10,12(27), 16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma. J. Med. Chem., 2011, 54(13), 4638-4658. doi: 10.1021/jm200326p PMID: 21604762
  11. Vazquez, M.L.; Kaila, N.; Strohbach, J.W.; Trzupek, J.D.; Brown, M.F.; Flanagan, M.E.; Mitton-Fry, M.J.; Johnson, T.A.; TenBrink, R.E.; Arnold, E.P.; Basak, A.; Heasley, S.E.; Kwon, S.; Langille, J.; Parikh, M.D.; Griffin, S.H.; Casavant, J.M.; Duclos, B.A.; Fenwick, A.E.; Harris, T.M.; Han, S.; Caspers, N.; Dowty, M.E.; Yang, X.; Banker, M.E.; Hegen, M.; Symanowicz, P.T.; Li, L.; Wang, L.; Lin, T.H.; Jussif, J.; Clark, J.D.; Telliez, J.B.; Robinson, R.P.; Unwalla, R. Identification of N-cis -3-Methyl(7 H -pyrrolo2,3- dpyrimidin-4-yl)aminocyclobutylpropane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases. J. Med. Chem., 2018, 61(3), 1130-1152. doi: 10.1021/acs.jmedchem.7b01598 PMID: 29298069
  12. Davis, R.R.; Li, B.; Yun, S.Y.; Chan, A.; Nareddy, P.; Gunawan, S.; Ayaz, M.; Lawrence, H.R.; Reuther, G.W.; Lawrence, N.J.; Schönbrunn, E. Structural insights into JAK2 inhibition by ruxolitinib, fedratinib, and derivatives thereof. J. Med. Chem., 2021, 64(4), 2228-2241. doi: 10.1021/acs.jmedchem.0c01952 PMID: 33570945
  13. Harrison, C.; Kiladjian, J.J.; Al-Ali, H.K.; Gisslinger, H.; Waltzman, R.; Stalbovskaya, V.; McQuitty, M.; Hunter, D.S.; Levy, R.; Knoops, L.; Cervantes, F.; Vannucchi, A.M.; Barbui, T.; Barosi, G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med., 2012, 366(9), 787-798. doi: 10.1056/NEJMoa1110556 PMID: 22375970
  14. Williams, N.K.; Bamert, R.S.; Patel, O.; Wang, C.; Walden, P.M.; Wilks, A.F.; Fantino, E.; Rossjohn, J.; Lucet, I.S. Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol., 2009, 387(1), 219-232. doi: 10.1016/j.jmb.2009.01.041 PMID: 19361440
  15. Rubbert-Roth, A.; Enejosa, J.; Pangan, A.L.; Haraoui, B.; Rischmueller, M.; Khan, N.; Zhang, Y.; Martin, N.; Xavier, R.M. Trial of upadacitinib or abatacept in rheumatoid arthritis. N. Engl. J. Med., 2020, 383(16), 1511-1521. doi: 10.1056/NEJMoa2008250 PMID: 33053283
  16. Levine, R.L.; Wadleigh, M.; Cools, J.; Ebert, B.L.; Wernig, G.; Huntly, B.J.P.; Boggon, T.J.; Wlodarska, I.; Clark, J.J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J.C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Fröhling, S.; Döhner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R.A.; Tefferi, A.; Griffin, J.D.; Eck, M.J.; Sellers, W.R.; Meyerson, M.; Golub, T.R.; Lee, S.J.; Gilliland, D.G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7(4), 387-397. doi: 10.1016/j.ccr.2005.03.023 PMID: 15837627
  17. Baxter, E.J.; Scott, L.M.; Campbell, P.J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G.S.; Bench, A.J.; Boyd, E.M.; Curtin, N.; Scott, M.A.; Erber, W.N.; Green, A.R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365(9464), 1054-1061. doi: 10.1016/S0140-6736(05)71142-9 PMID: 15781101
  18. James, C.; Ugo, V.; Le Couédic, J.P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garçon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J.L.; Constantinescu, S.N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434(7037), 1144-1148. doi: 10.1038/nature03546 PMID: 15793561
  19. Blanchard, S.; Lee, C.H.A.; Nagaraj, H.K.M.; Poulsen, A.; Sun, E.T.; Tan, Y.L.E.; William, A.D. Oxygen linked pyrimidine derivatives. US8415338B2, 2013.
  20. Jayaraman, R.; Pasha, M.; Williams, A.; Goh, K.; Ethirajulu, K. Metabolism and disposition of pacritinib (SB1518), an orally active janus kinase 2 inhibitor in preclinical species and humans. Drug Metab. Lett., 2015, 9(1), 28-47. doi: 10.2174/1872312809666150119105250 PMID: 25600203
  21. Shawky, A.M.; Almalki, F.A.; Abdalla, A.N.; Abdelazeem, A.H.; Gouda, A.M. A comprehensive overview of globally approved JAK inhibitors. Pharmaceutics, 2022, 14(5), 1001. doi: 10.3390/pharmaceutics14051001 PMID: 35631587
  22. Cafardi, J.; Miller, C.; Terebelo, H.; Tewell, C.; Benzaquen, S.; Park, D.; Egan, P.; Lebovic, D.; Pettit, K.; Whitman, E.; Tremblay, D.; Feld, J.; Buckley, S.; Roman-Torres, K.; Smith, J.; Craig, A.; Mascarenhas, J. Efficacy and safety of pacritinib vs placebo for patients with severe COVID-19. JAMA Netw. Open, 2022, 5(12), e2242918. doi: 10.1001/jamanetworkopen.2022.42918 PMID: 36469321

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bentham Science Publishers, 2023